drugset / Trial / NCT00453791

The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics

NCT00453791 ↗

Phase 1 Terminated 31 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

This study will be the First Time in Human Study (FTIH) aiming to assess the safety and tolerability of GW805858 for both single and repeat dose. The study also aims to assess safety and tolerability in mild asthmatic subjects as well as healthy volunteers.

Timeline

Start
2006-02-07
Primary completion
2006-04-10
Completion
2006-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GW805858 Unknown 150 ug Inhaled
Subject GW805858 Unknown 1200 ug Inhaled

Indications